Secretary Kennedy explained that nearly $500 million in contracts will be canceled.

The talks are a result of the MFN order, which seeks to make US drug prices match lower prices in international markets.

A new two-phase initiative aims to streamline facility approvals, reduce reliance on foreign pharmaceutical production, and bolster domestic supply chain resilience amid rising tariffs and reshoring investments.

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.

Access inequity is a multitude of smaller, interconnected operational and bureaucratic challenges.

Eli Lilly’s investigational, once-daily oral GLP-1 receptor agonist orforglipron produced a 12% body weight reduction in a Phase III trial, slightly lower than Novo Nordisk’s Wegovy.

Chai Discovery secures $70 million to revolutionize AI-driven drug discovery, enhancing antibody design and accelerating breakthroughs in medicine.

The company is streamlining its global workforce as part of a multi-year cost-cutting strategy, while raising its 2025 outlook on the strength of key pharmaceutical products.

Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one year and older.

XtalPi and DoveTree collaborate on a groundbreaking $6 billion drug discovery partnership, merging AI technology with biological expertise to tackle complex diseases.

With AI expected to play a significant role in drug approvals, how can companies build data sets that are ready for AI?

Gene Mack, CEO, Gain Therapeutics, explains how the company’s Magellan AI platform analyzes novel protein binding sites to identify and design drug candidates beyond what’s currently available in the public domain.

Currax Pharmaceuticals expands its impactful campaigns, showcasing real patient stories to empower those battling obesity and food cravings across the U.S.

The industry is facing calls to reduce prices while also bracing for increased tariffs.

Celltrion's Avtozma IV gains FDA approval for treating cytokine release syndrome, enhancing treatment options for patients aged 2 and older.

Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years with episodic migraine who weigh at least 99 lbs.

The deal brings the FDA-approved neuroblastoma therapy Danyelza (naxitamab-gqgk) to SERB Pharmaceuticals and advances its expansion in rare and pediatric oncology.

The move comes amidst a turbulent time at HHS.

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co-pay for a specific product.

Explore how Wounded Warrior Project and advocates like Morgan Fox promote mental health awareness and support for veterans facing PTSD and depression.

By using real-world data (RWD) and the insights derived from it, real-world evidence (RWE) earlier in research and development, drugmakers can make more informed decisions and reduce the financial risks that drive up drug prices.

The choice reflects the company's aims to revolutionize chronic care and expand global health solutions through innovative technology.

Gene Mack, CEO, GAIN Therapeutics, highlights early Phase Ib data showing GT-02287 may enhance neuroprotection across a wider spectrum of Parkinson’s patients regardless of genetic status.

The AI-driven collaboration will use Syntekabio’s DeepMatcher platform to identify new therapeutic targets for MetaVia’s DA-1241 following promising Phase IIa trial (NCT06054815) results in patients with presumed metabolic dysfunction-associated steatohepatitis.

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit over placebo in post-bunionectomy surgical pain relief.